telephone:+7 (8352) 222-490
Mail:info@interactive-plus.ru
rus eng


  1. Main
  2. Journal "Interactive science"
  3. No 4 (14)
  4. Synthetic cannabinoids: new matrix addiction
Центр научного сотрудничества "Интерактив плюс"
info@interactive-plus.ru
+7 (8352) 222-490
2130122532
Центр научного сотрудничества «Интерактив плюс»
RU
428000
Чувашская Республика
г.Чебоксары
ул.Гражданская, д.75
428000, Россия, Чувашская Республика, г. Чебоксары, улица Гражданская, дом 75
+7 (8352) 222-490
RU
428000
Чувашская Республика
г.Чебоксары
ул.Гражданская, д.75
56.125001
47.208966

Synthetic cannabinoids: new matrix addiction

Research Article
DOI: 10.21661/r-118680
Open Access
Monthly international scientific journal «Interactive science»
Creative commons logo
Published in:
Monthly international scientific journal «Interactive science»
Authors:
Antsyborov A.V. 1 , Mrykhin V.V. 2
Work direction:
Медицина
Rating:
Article accesses:
5225
Published in:
doaj
eLibrary.ru
Cited by:
1 articles
1 Mental Health Clinic «Psyche»
2 FSFEI of HE “Rostov State Medical University” of Russian Ministry of Health
For citation:
Antsyborov A. V., & Mrykhin V. V. (2017). Synthetic cannabinoids: new matrix addiction. Interactive science, 25-38. https://doi.org/10.21661/r-118680
  • Metadata
  • Full text
  • Metrics
  • Related articles
  • Cited by
UDC 61

Abstract

The majority of synthetic cannabinoids (SC), belongs to the group of so-called designer drugs distributed through illegal online shopping. The first reports of this group of psychoactive substances appeared in the 70s of the last century. Today, according to various estimates, there are over 160 varieties of synthetic cannabinoids, and this figure is increasing annually due to the synthesis of new substances in the group. This group of substances is designed to «copy» the psychoactive effects of cannabis. Initially, these substances were created solely for research purposes, to study the endocannabinoid system of the person. Natural THC is a partial agonist of cannabinoid receptors. Synthetic cannabinoids are full agonists CB1R and CB2R types of cannabinoid receptors. Most countries in the world, including Russia, at the legislative level have taken restrictive measures for preventing the spread of this group of substances. In order to circumvent the legislative measures, the producers of synthetic cannabinoids regularly changing the chemical formula. Each year, an increasing number of emergency hospital admissions associated with the use of synthetic cannabinoids in the peer-reviewed literature describes the deaths directly attributable to medical complications after taking synthetic cannabinoids. Numerous studies have proven the possibility of developing psychological dependence due to the use of synthetic cannabinoids. The proposed review of the literature is presented for the purpose of organizing data in the field of synthetic cannabinoids.

References

  1. 1. Cottencin O., Rolland B., Karila L. New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature. Curr Pharm Des 2014;20(25):4106–11 [Electronic resource]. – Access mode: http://www.emcdda.europa.eu/publications/pods/synthetic-cannabinoids
  2. 2. Mills B., Yepes A., Nugent K. Synthetic cannabinoids. Am J Med Sci 2015;350 (1):59–62.
  3. 3. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2016: trends and developments. Luxembourg: Publications Office of the European Union; 2016 [Electronic resource]. – Access mode: http://www.emcdda.europa.eu/system/files/publications/2637/TDAT16001ENN.pdf [p. 12, p. 30, p. 47. doi: 10.2810/04312. Catalog Number: TD-AT- 16–001-EN-N].
  4. 4. Johnson L.A., Johnson R.L., Portier R.B. Current «legal highs». J Emerg Med 2013;44(6):1108–15.
  5. 5. Karila L. Emergency of synthetic drugs in the general landscape of addiction. Rev Prat 2012;62(5):661–3.
  6. 6. European Monitoring Centre for Drugs and Drug Addiction. Perspectives on drugs – synthetic cannabinoids. Luxembourg: Publications Office of the European Union; 2016.
  7. 7. Simolka K., Lindigkeit R., Schiebel H.M., Papke U., Ernst L, Beuerle T. Analysis of synthetic cannabinoids in «spice-like» herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 2012;404 (1):157–71.
  8. 8. Spaderna M., Addy P.H., D'Souza D.C. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 2013;228(4):525–40.
  9. 9. Gunderson E.W., Haughey H.M., Ait-Daoud N., Joshi A.S., Hart CL. «Spice» and «K2» herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012;21(4):320–6.
  10. 10. Ernst L., Kruger K., Lindigkeit R., Schiebel H.M., Beuerle T. Synthetic cannabinoids in «spice-like» herbal blends: first appearance of JWH- 307 and recurrence of JWH-018 on the Ger- man market. Forensic Sci Int 2012;222(1–3):216–22.
  11. 11. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Thematic paper – Understanding the «Spice'' phenomenon. Luxembourg: Office for Official Publications of the European Communities; 2009 [doi: 10.2810/27063 (37 pp. p. 3, p.5, p.10, p.13, p.16, p.18, p.22)].
  12. 12. Dresen S., Ferreiros N., Putz M., Westphal F., Zimmermann R., Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive com- pounds. J Mass Spectrom 2010;45 (10):1186–94.
  13. 13. Atwood B.K., Lee D., Straiker A., Widlanski T.S., Mackie K. CP47,497-C8 and JWH073, commonly found in «Spice» herbal blends, are potent and efficacious CB (1) cannabinoid receptor agonists. Eur J Pharmacol 2011;659 (2–3):139–45.
  14. 14. Seely K.A., Patton A.L., Moran C.L., Womack M.L., Prather P.L., Fantegrossi W.E. et al. Forensic investigation of K2, Spice, and «bath salt» commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int 2013;233(1–3):416–22.
  15. 15. Fattore L. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry 2016;79(7):539–48.
  16. 16. Castellanos D., Gralnik L.M. Synthetic cannabinoids 2015: an update for pediatricians in clinical practice. World J Clin Pediatr 2016;5 (1):16–24.
  17. 17. European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in Europe. An update from the EU early warning system (March 2015). Luxembourg: Publications Office of the European Union; 20157 [Electronic resource]. – Access mode: http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf [ISBN: 978–92–9168–764–0. doi:10.2810/372415].
  18. 18. Fattore L., Fratta W. Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 2011; 5:60.
  19. 19. Debruyne D., Le Boisselier R. Emerging drugs of abuse: current perspectives on synthetic cannabinoids. Subst Abus Rehabil 2015; 6:113–29.
  20. 20. Abdulrahim D., Bowden-Jones O., on behalf of the NEPTUNE Expert Group. Guidance on the management of acute and chronic harms of club drugs and novel psychoactive substances. London: Novel Psychoactive Treatment UK Network (NEPTUNE); 201511 [Electronic resource]. – Access mode: http://neptune-clinical-guidance.co.uk/wp-content/uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf
  21. 21. Sarpong I., Jones F. A critical analysis of national policy relating to legal highs. Nurs Stand 2014;28(52):35–41.
  22. 22. Drug Enforcement Administration DoJ. Schedules of controlled substances: temporary placement of the synthetic cannabinoid MAB-CHMINACA into Schedule I. Final order. Fed Regist 2016;81(24):6171–5.
  23. 23. Drug Enforcement Administration DoJ. Schedules of controlled substances: temporary placement of three synthetic cannabinoids into Schedule I. Final order. Fed Regist 2015;80(20):5042–7.
  24. 24. Drug Enforcement Administration DoJ. Schedules of controlled substances: extension of temporary placement of PB-22, 5F-PB-22, AB- FUBINACA and ADB-PINACA in Schedule I of the controlled substances Act. Final order. Fed Regist 2016;81(24):6175–7.
  25. 25. Mounteney J., Griffiths P., Sedefov R., Noor A., Vicente J., Simon R. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015. Addiction 2016;111(1):34–48.
  26. 26. Rt Hon Karen Bradley MP, Home Office. Land-mark law to tackle legal highs commences later this month; 2016 [Electronic resource]. – Access mode: https://www.gov.uk/government/news/landmark-law-to-tackle-legal-highs-commences-later-this-month
  27. 27. Chavant F., Boucher A., Le Boisselier R., Deheul S., Debruyne D. New synthetic drugs in addictovigilance. Therapie 2015;70(2):167–89.
  28. 28. Csete J., Kamarulzaman A., Kazatchkine M., Altice F., Balicki M., Buxton J. et al. Public health and international drug policy. Lancet 2016;387(10026):1427–80. http://dx.doi.org/10.1016/S0140–6736(16)00619-X [Epub 2016 Mar 24].
  29. 29. Gunderson E.W., Haughey H.M., Ait-Daoud N., Joshi A.S., Hart C.L. A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus 2014;35(2):184–9.
  30. 30. Archer J.R., Dargan P.I., Lee H.M., Hudson S., Wood D.M. Trend analysis of anonymized pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances. Clin Toxicol (Phila) 2014;52(3):160–5.
  31. 31. Nelson M.E., Bryant S.M., Aks S.E. Emerging drugs of abuse. Emerg Med Clin North Am 2014;32(1):1–28.
  32. 32. Survey G.D. Global Drug Survey; [stable 1st January 2017] [Electronic resource]. – Access mode: http://www. globaldrugsurvey.com/wp-content/uploads/DRUG_SURVEY_FINAL_1.pdf
  33. 33. Smith K., Flatley J. Drug misuse declared: findings from the 2010/11 British crime survey. London: England and Wales, Home Office; 2011 p. 11–23 [Electronic resource]. – Access mode: https://www.gov.uk/government/uploads/system/uploads/attachmentdata/file/116333/hosb1211.pdf
  34. 34. Statistics OfN. Drug misuse declared: findings from the 2011/12 Crime Survey for England and Wales. London: Statistics OfN, Home Office; 2012.
  35. 35. Spanish Observatory on Drugs (SOOD). Survey on alcohol and drugs in Spain (EDADES); 2013 [Electronic resource]. – Access mode: http://www.emcdda.europa.eu/attachements.cfm/att_228526_EN_EMCDDA_NR2013_Spain. pdf
  36. 36. Inpes. Usages de psychoactifs illicites en France: les résultats du baromètre santé Inpes 2014; [stable 1st January 2017] [Electronic resource]. – Access mode: http://www.inpes.sante.fr/30000/ actus2015/023-drogues-illicites.asp
  37. 37. Spilka S, Le Nezet O, Ngantcha M, Beck F. Drug use among 17-year-olds: results of the ESCAPAD 2014 survey. Tendances 2015;100: 1–8.
  38. 38. Johnston L.D., O’Malley P.M., Miech R.A., Bachman J.G., Schulenberg J.E. Monitoring the Future national survey results on drug use: 1975–2014: overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2015 [Electronic resource]. – Access mode: http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2014.pdf
  39. 39. ESPAD Group, EMCDDA. ESPAD Report 2015 – results from the European School Survey Project on Alcohol and Other Drugs; 2015, http://www.espad.org/sites/espad.org/ files/ESPAD_report_2015.pdf [p. 41, 62, 84].
  40. 40. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Hospital emergency presentations and acute drug toxicity in Europe: update from the Euro-DEN Plus research group and the EMCDDA. Luxembourg: Publications Office of the European Union; 201614 [Electronic resource]. – Access mode: http://www.emcdda. europa.eu/system/files/publications/2973/TD0216713ENN-1_Final%20pdf.pdf [doi: 10.2810/894142].
  41. 41. Drugs in Prison© The Centre for Social Justice. Centre for Social Justice; 2015 [Electronic resource]. – Access mode: http://www.centreforsocialjustice.org.uk/core/wp-content/uploads/2016/08/CSJJ3090_Drugs_in_Prison.pdf
  42. 42. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord 2005;4(5):507–30.
  43. 43. Pertwee R.G., Howlett A.C., Abood M.E., Alexander S.P., Di Marzo V., Elphick M.R. et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB (1) and CB (2). Pharmacol Rev 2010;62(4):588–631.
  44. 44. Fantegrossi W.E., Moran J.H., Radominska-Pandya A., Prather P.L. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta (9)-THC: mechanism underlying greater toxicity? Life Sci 2014;97 (1):45–54.
  45. 45. De Luca M.A., Bimpisidis Z., Melis M., Marti M., Caboni P., Valentini V. et al. Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. Neuropharmacology 2015; 99:705–14.
  46. 46. Tai S., Fantegrossi W.E., Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential. Curr Addict Rep 2014;1(2):129–36.
  47. 47. Van Amsterdam J., Brunt T., Van Den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29(3):254-63. http://dx.doi.org/10.1177/0269881114565142 [Epub 2015 Jan 13].
  48. 48. Morgan C.J., Schafer G., Freeman T.P., Curran H.V. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010;197(4):285–90. http://dx.doi.org/10.1192/bjp.bp.110.077503
  49. 49. Van Amsterdam J., Brunt T., van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 2015;29(3):254-63.
  50. 50. Breitenbach S., Rowe W.F., McCord B., Lurie I.S. Assessment of ultra-high performance supercritical fluid chromatography as a separation technique for the analysis of seized drugs: applicability to synthetic cannabinoids. J Chromatogr A 2016; 1440:201–11. http://dx.doi. org/10.1016/j.chroma.2016.02.047 [Epub 2016 Feb 17].
  51. 51. Howlett A.C. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54 (2):161–202.
  52. 52. Thakur G.A., Nikas S.P., Duclos Jr R.I., Makriyannis A. Methods for the synthesis of cannabinergic ligands. Methods Mol Med 2006; 123:113–48.
  53. 53. Prosser J.M., Nelson L.S. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012;8(1):33–42.
  54. 54. Petit A., Karila L., Sananes M., Lejoyeux M. Mephedrone: a new synthetic drug. Presse Med 2013;42(10):1310–6.
  55. 55. Gurney S.M., Scott K.S., Kacinko S.L., Presley B.C., Logan B.K. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 2014;26(1):53–78.
  56. 56. Auwarter V., Dresen S., Weinmann W., Müller M., Pütz M., Ferreirós N. Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009;44(5):832–7.
  57. 57. Barratt M.J.1, Cakic V., Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 2013;32(2):141–6. http://dx.doi.org/10.1111/j.1465–3362.2012.00519.x
  58. 58. Aoun E.G., Christopher P.P., Ingraham J.W. Emerging drugs of abuse: clinical and legal considerations. Med Health R I 2014;97(6):41- 5.
  59. 59. Bush D.M., Woodwell D.A. Update: drug-related emergency department visits involving synthetic cannabinoids. The CBHSQ Report. Rockville (MD): substance abuse and mental health services administration (US). Int J Drug Policy 2013–2014; 32:77–84. http://dx.doi.org/10.1016/j. drugpo.2016.03.007 [PMID: 27030867] [Electronic resource]. – Access mode: https://www.samhsa.gov/data/sites/default/files/SR-1378/SR-1378.pdf
  60. 60. Weaver M.F., Hopper J.A., Gunderson E.W. Designer drugs 2015: assessment and management. Addict Clin Pract 2015; 10:8.
  61. 61. Heath T.S., Burroughs Z., Thompson A.J., Tecklenburg F.W. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther 2012;17(2):177–81.
  62. 62. Hermanns-Clausen M., Kneisel S., Hutter M., Szabo B., Auwarter V. Acute intoxication by synthetic cannabinoids – four case reports. Drug Test Anal 2013;5(9–10):790–4.
  63. 63. Atik S.U., Dedeoglu R., Varol F., Cam H., Eroglu A.G., Saltik L. Cardiovascular side effects related with use of synthetic cannabinoids «bonsai»: two case reports. Turk Pediatri Ars 2015;50(1):61–4.
  64. 64. Lapoint J., James L.P., Moran C.L., Nelson L.S., Hoffman R.S., Moran J.H. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol (Phila) 2011;49(8):760–4.
  65. 65. Young A.C., Schwarz E., Medina G., Obafemi A., Feng S.Y., Kane C. et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012;30(7):1320e5–0e7.
  66. 66. McIlroy G., Ford L., Khan J.M. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol 2016;17(1):2.
  67. 67. Von Der Haar J., Talebi S., Ghobadi F., Singh S., Chirurgi R., Rajeswari P. et al. Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med 2016;50 (2):258–62.
  68. 68. Wells D.L., Ott C.A. The «new» marijuana. Ann Pharmacother 2011;45(3):414–7.
  69. 69. Pacher P., Batkai S., Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 2005;(168):599–625.
  70. 70. Kane E.M., Hinson J.S., Jordan C.D., Paziana K., Sauber N.J., Rothman R.E., et al. Bradycardia and hypotension after synthetic cannabinoid use: a case series. Am J Emerg Med 2016;34 (10): 2055.e1–5. e. http://dx.doi.org/10.1016/j.ajem.2016.03.007 [Epub 2016 Mar 4 (PMID: 27037136)].
  71. 71. Alhadi S., Tiwari A., Vohra R., Gerona R., Acharya J., Bilello K. High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use. J Med Toxicol 2013;9(2):199–206.
  72. 72. Loschner A., Cihla A., Jalali F., Ghamande S. Diffuse alveolar hemorrhage: add «green-house effect» to the growing list. Chest 2011; 140:149A [http://journal.publications.chestnet.org/article.aspx?articleid=1088295 (stable 1st January 2017)].
  73. 73. Drenzek C., Geller R., Steck A., Arnold J., Lopez G., Gerona R. et al. Notes from the field: severe illness associated with synthetic cannabinoid use-Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep 2013 [http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6246a7.htm (stable 1st January 2016)].
  74. 74. Biswas A., Patel V., Jantz M., Mehta H.J. Synthetic cannabinoids as a cause for black carbonaceous bronchoalveolar lavage. BMJ Case Rep 2015;2015. http://dx.doi.org/10.1136/bcr-2015–211391 [PMID: 26220985. pii: bcr2015211391].
  75. 75. Karila L., Roux P., Rolland B., Benyamina A., Reynaud M., Aubin H.J. et al. Acute and long term effects of cannabis use: a review. Curr Pharm Des 2014;20(25):4112–8.
  76. 76. Hopkins C.Y., Gilchrist B.L. A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 2013;45 (4):544–6.
  77. 77. Pendergraft 3rd W.F., Herlitz L.C., Thornley-Brown D., Rosner M., Niles J.L. Nephrotoxic effects of common and emerging drugs of abuse. Clin J Am Soc Nephrol 2014;9 (11):1996–2005.
  78. 78. Tait R.J., Caldicott D., Mountain D., Hill S.L., Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 2016;54(1):1–13.
  79. 79. Park M., Yeon S., Lee J., In S. Determination of XLR-11 and its metabolites in hair by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2015; 114:184–9.
  80. 80. Centers for Disease C. Prevention. Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013;62(6):93–8.
  81. 81. Thornton S.L., Wood C., Friesen M.W., Gerona R.R. Synthetic cannabinoid use associated with acute kidney injury. Clin Toxicol (Phila) 2013;51(3):189–90.
  82. 82. Kamel M., Thajudeen B. A case of acute kidney injury and calcium oxalate deposition associated with synthetic cannabinoids. Saudi J Kidney Dis Transpl 2015;26(4):802–3.
  83. 83. Zhao A., Tan M., Maung A., Salifu M, Mallappallil M. Rhabdomyolysis and acute kidney injury requiring dialysis as a result of concomitant use of atypical neuroleptics and synthetic cannabinoids. Case reports in nephrology 2015; 2015:235982.
  84. 84. Durand D., Delgado L.L., de la Parra-Pellot D.M., Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses 2015;8(4):205–8.
  85. 85. Sweeney B., Talebi S., Toro D., Gonzalez K., Menoscal J.P., Shaw R. et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med 2016;34(1):121e1-2e.
  86. 86. Inci R., Kelekci K.H., Oguz N., Karaca S., Karadas B., Bayrakci A. Dermatological aspects of synthetic cannabinoid addiction. Cutan Ocul Toxicol 2016;1–7. http://dx.doi.org/ 10.3109/15569527.2016.1169541 [PMID: 27028361].
  87. 87. Cha H.J., Seong Y.H., Song M.J., Jeong H.S., Shin J, Yun J. et al. Neurotoxicity of synthetic cannabinoids JWH-081 and JWH-210. Biomol Ther (Seoul) 2015;23(6):597–603.
  88. 88. Behonick G., Shanks K.G., Firchau D.J., Mathur G., Lynch C.F., Nashelsky M. et al. Four post-mortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol 2014;38(8):559–62.
  89. 89. Rose D.Z., Guerrero W.R., Mokin M.V., Gooch C.L., Bozeman A.C. Pearson JM, et al. Hemorrhagic stroke following use of the synthetic marijuana «spice''. Neurology 2015;85 (13):1177–9.
  90. 90. Takematsu M., Hoffman R.S., Nelson L.S., Schechter J.M., Moran J.H., Wiener S.W. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol (Phila) 2014;52(9):973–5.
  91. 91. Bernson-Leung M.E., Leung L.Y., Kumar S. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Dis 2014;23(5):1239–41.
  92. 92. Freeman M.J., Rose D.Z., Myers M.A., Gooch C.L., Bozeman A.C., Burgin W.S. Ischemic stroke after use of the synthetic marijuana «spice». Neurology 2013;81(24):2090–3.
  93. 93. Ustundag M.F., Ozhan Ibis E., Yucel A., Ozcan H. Synthetic cannabis-induced mania. Case reports in psychiatry 2015; 2015:310930.
  94. 94. Müller H.H., Kornhuber J., Sperling W. The behavioral profile of spice and synthetic cannabinoids in humans. Brain Res Bull 2016;126 (Pt 1):3–7. http://dx.doi.org/10.1016/j. brainresbull.2015.10.013 [Epub 2015 Nov 6. PMID: 26548494].
  95. 95. Peglow S., Buchner J., Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict 2012;21 (3):287–8.
  96. 96. Klavz J, Gorenjak M, Marinsek M. Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non- fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4- CMC. Forensic Sci Int 2016; 265:121–4.
  97. 97. Meijer K.A., Russo R.R., Adhvaryu D.V. Smoking synthetic marijuana leads to self-mutilation requiring bilateral amputations. Orthopedics 2014;37(4): e391–4.
  98. 98. Khan M., Pace L., Truong A., Gordon M., Moukaddam N. Catatonia secondary to synthetic cannabinoid use in two patients with no previous psychosis. Am J Addict 2016;25 (1):25–7.
  99. 99. Zaurova M., Hoffman R.S., Vlahov D., Manini A.F. Clinical effects of synthetic cannabinoid receptor agonists compared with marijuana in emergency department patients with acute drug overdose. J Med Toxicol 2016;12(4):335-40. http://dx.doi.org/10.1007/s13181–016- 0558–4 [Available on 2017–12–01. Epub 2016 Jun 2. PMID: 27255136. PMCID: PMC5135672].
  100. 100. Tyndall J.A., Gerona R., De Portu G., Trecki J., Elie M.C., Lucas J. et al. An outbreak of acute delirium from exposure to the synthetic cannabinoid AB-CHMINACA. Clin Toxicol (Phila) 2015;53(10):950–6.
  101. 101. Morkl S., Blesl C., Wurm W.E., Tmava A. Acute psychosis after consumption of synthetic cannabinoids. Fortschr Neurol Psychiatr 2016;84 (3):150–4.
  102. 102. Miliano C., Serpelloni G., Rimondo C., Mereu M., Marti M., De Luca M.A. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci 2016; 10:153.
  103. 103. Sampson C.S., Bedy S.M., Carlisle T. Withdrawal seizures seen in the setting of synthetic cannabinoid abuse. Am J Emerg Med 2015;33 (11):1712e3.
  104. 104. Macfarlane V., Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 2015;34 (2):147–53.
  105. 105. Andrabi S., Greene S., Moukaddam N., Li B. New drugs of abuse and withdrawal syndromes. Emerg Med Clin North Am 2015;33 (4):779–95.
  106. 106. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., Nees J.A., Spanagel R., Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of «spice gold»'. Dtsch Arztebl Int 2009;106(27):464–7.
  107. 107. Nacca N., Vatti D., Sullivan R., Sud P., Su M., Marraffa J. The synthetic cannabinoid withdrawal syndrome. J Addict Med 2013;7 (4):296–8.
  108. 108. Labay L.M., Caruso J.L., Gilson T.P., Phipps R.J., Knight L.D., Lemos N.P., et al. Synthetic cannabinoid drug use as a cause or contributory cause of death. Forensic Sci Int 2016;260: 31–9.
  109. 109. Hasegawa K., Wurita A., Minakata K., Gonmori K., Nozawa H., Yamagishi I. et al. Post-mortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicol 2015;33(2):380–7.
  110. 110. Ibrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol 2014;2014: 120607.
  111. 111. Davis C, Boddington D. Teenage cardiac arrest following abuse of synthetic cannabis. Heart Lung Circ 2015;24(10): e162–3.
  112. 112. Shanks K.G., Clark W., Behonick G. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol 2016;40(3):236–9.
  113. 113. Shanks K.G., Behonick G.S. Death after use of the synthetic cannabinoid 5F-AMB. Forensic Sci Int 2016;262: e21–4. http://dx.doi.org/10.1016/j.forsciint.2016.03.004 [Epub 2016 Mar 16. PMID: 27017174].
  114. 114. Shanks K.G., Winston D., Heidingsfelder J., Behonick G. Case reports of synthetic cannabinoid XLR-11 associated fatalities. Forensic Sci Int 2015;252: e6–9.
  115. 115. Adamowicz P. Fatal intoxication with synthetic cannabinoid MDMB-CHMICA. Forensic Sci Int 2016;261: e5–10.
  116. 116. European Monitoring Centre for Drugs and Drug Addiction. European drug report 2014: trends and developments. Luxembourg: Publications Office of the European Union; 201436 [Electronic resource]. – Access mode: http://www.emcdda.europa.eu/ system/files/publications/963/ TDAT14001ENN.pdf [doi:10.2810/32306].
  117. 117. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EMCDDA-Europol Joint Report on a new psychoactive sub- stance: methyl 2-[[1-(cyclohexylmethyl) indole-3-carbonyl] amino]-3,3-dimethylbutanoate (MDMB-CHMICA), Joint Reports. Luxembourg: Publications Office of the European Union; 201611, http://emcdda.europa.eu/system/files/publications/2873/2016.4528_WEB.pdf [doi:10.2810/08132 I].
  118. 118. Смерть от спайсов – статистика смертности 2016 [Электронный ресурс]. – Режим доступа: http://netnarkotiki.ru/blog/smert-ot-spajsov.html (дата обращения: 01.02.2017).
  119. 119. Мрыхин В.В. Психиатрические аспекты употребления дизайнерских наркотиков и новых психоактивных веществ [Текст] / В.В. Мрыхин, А.В. Анцыборов // Интерактивная наука. – 2017. – №12. – С. 64–74.
  120. 120. Асадуллин А.Р. Анализ распространенности синтетических каннабиноидов в Республике Башкортостан / А.Р. Асадуллин // Медицинский вестник Башкортостана. – 2016. – №6. – С. 61–64.
  121. 121. Асадуллин А.Р. Approach to Classifying «Design» Drugs and New Potentially Dangerous Chemical Substances, With a Brief Review of the Problem / А.Р. Асадуллин, Е.Х. Галеева, Э.А. Ахметова, И.В. Николаев // International Journal Of Environmental & Science Education 2016, Vol. 11, №14, 6697–6703 DOI: 10.12973/ijese.2016.565a

Comments(0)

When adding a comment stipulate:
  • the relevance of the published material;
  • general estimation (originality and relevance of the topic, completeness, depth, comprehensiveness of topic disclosure, consistency, coherence, evidence, structural ordering, nature and the accuracy of the examples, illustrative material, the credibility of the conclusions;
  • disadvantages, shortcomings;
  • questions and wishes to author.